{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:13:50Z","timestamp":1761894830118},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.leukres.2008.11.027","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T04:38:49Z","timestamp":1232685529000},"page":"1079-1081","source":"Crossref","is-referenced-by-count":23,"title":["Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature"],"prefix":"10.1016","volume":"33","author":[{"given":"Salvatore","family":"Guastafierro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Celentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giovanna","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.11.027_bib1","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukaemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.027_bib2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.027_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.11.027_bib4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","article-title":"Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in the chronic phase: comparison with historic data","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.11.027_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.027_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.027_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20096","article-title":"Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases","volume":"76","author":"Higashi","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2008.11.027_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1532\/IJH97.06187","article-title":"Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy","volume":"85","author":"Okabe","year":"2007","journal-title":"Int J Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2008.11.027_bib9","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.11.027_bib10","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.027_bib11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2005.01.009","article-title":"Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) Outcome of discontinuation of imatinib therapy after achieving a molecular remission.","volume":"29","author":"Ali","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.11.027_bib12","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.11.027_bib13","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.11.027_bib14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.leukres.2006.03.011","article-title":"Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon","volume":"30","author":"Breccia","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.11.027_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/10428190802043903","article-title":"Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha","volume":"49","author":"Verma","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2008.11.027_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alpha","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.11.027_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000089476","article-title":"Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukaemia","volume":"115","author":"Verbeek","year":"2006","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2008.11.027_bib18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2008.11.027_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mehy.2007.03.040","article-title":"Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: implications for the outcome of imatinib treatment and discontinuation","volume":"70","author":"Wodarz","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.leukres.2008.11.027_bib20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/leu.2008.94","article-title":"Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation","volume":"22","author":"Carella","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.027_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-\u03b1, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T04:27:32Z","timestamp":1545452852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608005225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0145212608005225"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.11.027","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}